Nasal Spray Range (Fluticasone Furoate / Oxymetazoline / Mometasone / Azelastine)
Product Description
Biodeal pharmaceuticals Ltd.
-
Country/Region:India
-
Founded:2005
-
On CPHI since:2017
-
Certificates:5
-
Employees:500 - 999
Company types
Primary activities
Categories
Specifications
Biodeal pharmaceuticals Ltd.
-
Country/Region:India
-
Founded:2005
-
On CPHI since:2017
-
Certificates:5
-
Employees:500 - 999
Company types
Primary activities
More Products from Biodeal pharmaceuticals Ltd. (5)
-
Product Nasal Spray Range
Fluticasone Furoate 27.5 mcg Fluticasone Furoate 27.5 mcg + Oxymetazoline 50 mcg Mometasone Furoate 50 mcg Azelastine Hydrochloride 140 mcg Intranasal corticosteroids, combination decongestant, and antihistamine spray — allergic & non-allergic rhinitis range -
Product Injectables - FULL CARBAPENEM Range
MECHANISM OF ACTION
Carbapenems are broad-spectrum beta-lactam antibiotics that bind penicillin-binding proteins (PBPs) in the bacterial cell wall, inhibiting peptidoglycan cross-linking and causing cell lysis. Their structure confers high stability against most beta-lactamases, including many that in... -
Product Midazolam Nasal Spray
Benzodiazepine, intranasal route, seizure rescue / procedural sedation -
Product Rifaximin Sachet
Gut selective antibiotic
Minimal Systemic absorption
Broad Spectrum in nature
-
Product Vonoprazan Tablets
Potassium-competitive acid blocker (P-CAB); GERD, H. pylori eradication, peptic ulcer disease
Biodeal pharmaceuticals Ltd. resources (3)
-
Brochure Biodeal Pharmaceuticals - Company Profile
Biodeal Pharmaceuticals Limited is a WHO-GMP and PIC/S certified, USFDA-compliant Contract Development and Manufacturing Organisation (CDMO) founded in 2005. Headquartered in Noida with manufacturing facilities across Himachal Pradesh, we serve 1000+ clients across 80+ countries with a portfolio of 1,000+ formulations and 100+ global regulatory registrations.
India's leading nasal spray CDMO. Largest innovative range globally across 20+ formulations including complex molecules. State-of-the-art nasal filling line with advanced plume geometry, particle size and spray pattern testing. Three DCGI approvals in 2024–25. Active pipeline of India-first and global-first molecules.
Injectables: dedicated advanced sterile manufacturing facility at Paonta Sahib. 12 production lines across general injectables, broad-range carbapenems and hormone injectables.




